3Knowledge and impact
Where the gaps are, which ones close with repetition, which need targeted refreshers, and what they are worth.
For commercial excellence and financeIllustrative data
Initial gap rate by countryfirst-attempt incorrect answers
Spain22.4%
France19.1%
Germany24.2%
Italy16.5%
Portugal31.8%
48,600questions viewed
22.8%average initial gap rate
Top questions by final gap ratestill answered wrong after repetition
Which patients should not use the Lite version?41%
What did the pivotal study measure first?35%
How long does set-up take versus the previous model?27%
Which claim is not approved for promotion?22%
What is the recommended follow-up interval?19%
96,400total answers
13.9%average final gap rate
Initial vs final gap rate by category
InitialFinal
27%20%
29%22%
36%31%
35%30%
33%28%
35%26%
Product overviewTechnical featuresClinical dataSafetyCompetitorsPatient selection
Key questions
| Initial | Final | Repetitions |
|---|
| Which claim is not approved? | 32% | 21% | 2.1 |
| Primary endpoint of the pivotal study? | 79% | 50% | 2.2 |
| Pressure range of the Lite version? | 87% | 64% | 2.2 |
| Retreatment rate in the long-term study? | 90% | 72% | 2.5 |
2.1
average repetitions per question
1,216
gaps open after challenges
78
key gaps corrected with targeted refreshers
Economic impact
Projection with your own parametersGaps: identified and still open
Non-key identifiedNon-key openKey identifiedKey open
€499,375Estimated value at risk
€257,750Estimated reduction in value at risk
€241,625Estimated remaining value at risk
This illustrative model uses agreed values per gap and verified gap closure to estimate changes in value at risk. It does not measure recovered sales.